SUBSCRIBE
SUBSCRIBE
News   Drug Development

Genmab A/S, GlaxoSmithKline (JOBS) Cancer Drug Arzerra Disappoints in Phase 3 Study

August 18, 2009 | 
1 min read
Bookmark and Share

Reuters -- Disappointing clinical results sent shares in Danish biotechnology company Genmab tumbling 26 percent on Tuesday as investors questioned sales prospects for its key drug Arzerra in treating blood cancer.
Clinical research Phase III
GlaxoSmithKline
MORE ON THIS TOPIC
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Artwork magazine collage picture of serious confident lady looking big enlargement glass isolated drawing background.
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
 · 
3 min read
 · 
Tristan Manalac
Illustration showing scientist climbing up DNA spiral staircase
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
 · 
3 min read
 · 
Tristan Manalac
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac